We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ultragenyx's Dojolvi Gets FDA Nod to Treat Rare Disease
Read MoreHide Full Article
Ultragenyx Pharmaceutical Inc. (RARE - Free Report) announced that the FDA has approved UX007 (triheptanoin) as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD). The drug will be marketed under the brand name,Dojolvi. The approval date comes a month ahead of the action date of Jul 31.
Ultragenyx expects Dojolvi to be available to patients in the next 30 days.
Long-chain fatty acid oxidation disorders are a group of rare conditions that prevent the body from breaking down certain fats into energy, leaving patientswith low blood sugar, muscle ruptures, muscle weakness and heart disease.
The approval of the drug will lead to increased sales for the company.
Shares of Ultragenyx have surged 83.1% year to date compared with the industry’s growth of 12.5%.
This is the second approval in June 2020 that the company received fromthe FDA for a rare disease, which had no approved therapy. In June, the FDA also approved the company’s Crysvita to treat tumor-induced osteomalacia, which is a rare disease that causes weakened or soft bones.
The company also has some gene therapy candidates in its pipeline. These include DTX301, which is an adeno-associated virus 8 (AAV8) being evaluated for the treatment of patients with Ornithine transcarbamylase (OTC) deficiency. DTX401 is also an AAV8 gene-therapy candidate, currently being evaluated for the treatment of patients with glycogen storage disease type Ia (GSDIa).
Further, the company has an agreement with Bayer (BAYRY - Free Report) to develop adeno-associated virus gene therapies, one of which isDTX 201, for the treatment of hemophilia A.
Emergent’s earnings per share estimates have increased from $3.43 to $4.03 for 2020 and from $3.54 to $3.73 for 2021 in the past 60 days.
Ligand Pharmaceuticals’ earnings per share estimates have increased from $3.45 to $3.70 for 2020 and from $4.00 to $4.40 for 2021 in the past 60 days.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
Ultragenyx's Dojolvi Gets FDA Nod to Treat Rare Disease
Ultragenyx Pharmaceutical Inc. (RARE - Free Report) announced that the FDA has approved UX007 (triheptanoin) as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD). The drug will be marketed under the brand name,Dojolvi. The approval date comes a month ahead of the action date of Jul 31.
Ultragenyx expects Dojolvi to be available to patients in the next 30 days.
Long-chain fatty acid oxidation disorders are a group of rare conditions that prevent the body from breaking down certain fats into energy, leaving patientswith low blood sugar, muscle ruptures, muscle weakness and heart disease.
The approval of the drug will lead to increased sales for the company.
Shares of Ultragenyx have surged 83.1% year to date compared with the industry’s growth of 12.5%.
This is the second approval in June 2020 that the company received fromthe FDA for a rare disease, which had no approved therapy. In June, the FDA also approved the company’s Crysvita to treat tumor-induced osteomalacia, which is a rare disease that causes weakened or soft bones.
The company also has some gene therapy candidates in its pipeline. These include DTX301, which is an adeno-associated virus 8 (AAV8) being evaluated for the treatment of patients with Ornithine transcarbamylase (OTC) deficiency. DTX401 is also an AAV8 gene-therapy candidate, currently being evaluated for the treatment of patients with glycogen storage disease type Ia (GSDIa).
Further, the company has an agreement with Bayer (BAYRY - Free Report) to develop adeno-associated virus gene therapies, one of which isDTX 201, for the treatment of hemophilia A.
Ultragenyx Pharmaceutical Inc. Price
Ultragenyx Pharmaceutical Inc. price | Ultragenyx Pharmaceutical Inc. Quote
Zacks Rank and Stocks to Consider
Ultragenyx is a Zacks Rank #3 (Hold) stock.
Some better-ranked stocks in the biotech sector are Emergent Biosolutions Inc. (EBS - Free Report) and Ligand Pharmaceuticals Inc. (LGND - Free Report) , both carrying a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Emergent’s earnings per share estimates have increased from $3.43 to $4.03 for 2020 and from $3.54 to $3.73 for 2021 in the past 60 days.
Ligand Pharmaceuticals’ earnings per share estimates have increased from $3.45 to $3.70 for 2020 and from $4.00 to $4.40 for 2021 in the past 60 days.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>